Published in Br J Pharmacol on August 26, 2003
The inflammatory response in stroke. J Neuroimmunol (2006) 5.33
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab (2012) 2.25
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation (2008) 1.92
The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation (2010) 1.54
Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis (2012) 1.47
Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci U S A (2011) 1.32
Targeting astrocytes for stroke therapy. Neurotherapeutics (2010) 1.25
LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation (2011) 1.25
Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab (2012) 1.20
Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study. J Neuroinflammation (2011) 1.13
Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation (2011) 1.12
Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS? Br J Pharmacol (2010) 1.12
Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci (2008) 1.11
The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med (2007) 1.11
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab (2010) 1.08
Glyceraldehyde-3-phosphate dehydrogenase versus toluidine blue as a marker for infarct volume estimation following permanent middle cerebral artery occlusion in mice. Exp Brain Res (2006) 1.05
Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci (2012) 1.04
Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res (2010) 1.01
Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem (2014) 0.99
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation (2005) 0.99
Interleukin-1 and acute brain injury. Front Cell Neurosci (2015) 0.95
The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review. Aging Dis (2014) 0.90
Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study. J Appl Physiol (1985) (2011) 0.89
The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation (2014) 0.88
Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury. Mediators Inflamm (2012) 0.88
Activation of Transient Receptor Potential Vanilloid 4 Increases NMDA-Activated Current in Hippocampal Pyramidal Neurons. Front Cell Neurosci (2013) 0.88
AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc Natl Acad Sci U S A (2015) 0.86
Ischemic preconditioning-induced neuroprotection is associated with differential expression of IL-1beta and IL-1 receptor antagonist in the ischemic cortex. J Neuroimmunol (2009) 0.86
Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease. Cytokine (2009) 0.86
Accelerated recovery from acute hypoxia in obese mice is due to obesity-associated up-regulation of interleukin-1 receptor antagonist. Endocrinology (2009) 0.85
Inflammatory Disequilibrium in Stroke. Circ Res (2016) 0.83
Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective. J Aging Res (2011) 0.83
The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. Int J Stem Cells (2012) 0.82
Resveratrol alleviates nerve injury after cerebral ischemia and reperfusion in mice by inhibiting inflammation and apoptosis. Int J Clin Exp Med (2015) 0.82
Mechanisms of estrogens' dose-dependent neuroprotective and neurodamaging effects in experimental models of cerebral ischemia. Int J Mol Sci (2011) 0.81
Interleukin-1β in Central Nervous System Injury and Repair. Eur J Neurodegener Dis (2012) 0.80
Long-term functional recovery and compensation after cerebral ischemia in rats. Behav Brain Res (2014) 0.79
Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update. Transl Stroke Res (2016) 0.79
Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis. PLoS One (2013) 0.79
A Systematic, Integrated Study on the Neuroprotective Effects of Hydroxysafflor Yellow A Revealed by (1)H NMR-Based Metabonomics and the NF-κB Pathway. Evid Based Complement Alternat Med (2013) 0.78
Inhibition of soluble epoxide hydrolase after cardiac arrest/cardiopulmonary resuscitation induces a neuroprotective phenotype in activated microglia and improves neuronal survival. J Cereb Blood Flow Metab (2013) 0.77
Cinnamaldehyde inhibits inflammation and brain damage in a mouse model of permanent cerebral ischaemia. Br J Pharmacol (2015) 0.77
Baifuzi reduces transient ischemic brain damage through an interaction with the STREX domain of BKCa channels. Cell Death Dis (2010) 0.76
Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat Model. Biomol Ther (Seoul) (2017) 0.75
Effect of Low-Dose Alcohol Consumption on Inflammation Following Transient Focal Cerebral Ischemia in Rats. Sci Rep (2017) 0.75
Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke (1989) 21.77
Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci (1999) 10.61
A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab (1990) 8.26
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 6.18
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 3.70
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today (1991) 2.91
Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke (1995) 2.81
Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol (1999) 2.28
Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke (2002) 2.25
Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 2.24
Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci (2001) 2.20
Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull (1992) 1.80
Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab (1996) 1.72
Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab (1998) 1.57
Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol (1999) 1.39
Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol (1994) 1.38
Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke (1995) 1.31
Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol (1995) 1.28
Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol (1996) 1.28
Delayed postischemic hyperthermia in awake rats worsens the histopathological outcome of transient focal cerebral ischemia. Stroke (1996) 1.18
Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci (1998) 1.17
Exacerbation of ischemic brain damage by localized striatal injection of interleukin-1beta in the rat. J Cereb Blood Flow Metab (1998) 1.16
Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke (2002) 1.15
Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am J Physiol (1996) 1.09
Dorsal cerebral arterial collaterals of the rat. Anat Rec (1982) 1.06
Effect of mild hyperthermia on the ischemic infarct volume after middle cerebral artery occlusion in the rat. Neurology (1991) 1.04
Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament. Brain Res (1994) 1.04
Spontaneous hyperthermia and its mechanism in the intraluminal suture middle cerebral artery occlusion model of rats. Stroke (1999) 1.01
Postischemic spontaneous hyperthermia and its effects in middle cerebral artery occlusion in the rat. Exp Neurol (2000) 0.99
Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience (2000) 0.96
Filament size influences temperature changes and brain damage following middle cerebral artery occlusion in rats. Exp Brain Res (2001) 0.94
Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci (1995) 0.93
The ischaemic penumbra. Curr Opin Neurol (2001) 0.91
Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat. J Neurosci Methods (2002) 0.88
Role of endogenous interleukin-1 receptor antagonist in regulating fever induced by localised inflammation in the rat. J Physiol (2001) 0.87
Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother (2002) 0.85
From the Food and Drug Administration. JAMA (2002) 0.79
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Interleukin-1 and neuronal injury. Nat Rev Immunol (2005) 3.85
Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell (2005) 2.63
Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci (2007) 2.47
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci (2008) 2.21
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci (2007) 1.80
CNS injury: the role of the cytokine IL-1. Vet J (2004) 1.65
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J Biol Chem (2001) 1.52
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1 beta and IL-1 alpha from murine macrophages. J Immunol (2003) 1.39
Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood (2010) 1.38
Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma (2007) 1.36
Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab (2007) 1.34
Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem (2006) 1.27
A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab (2009) 1.22
Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab (2012) 1.20
Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis (2011) 1.18
A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol (2003) 1.17
Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci (2003) 1.14
Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol (2007) 1.12
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol (2012) 1.10
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem (2002) 1.09
Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech (2012) 1.09
Experimental stroke-induced changes in the bone marrow reveal complex regulation of leukocyte responses. J Cereb Blood Flow Metab (2010) 1.08
Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab (2009) 1.06
Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab (2003) 1.06
Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res (2002) 1.06
Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia (2006) 1.06
Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia (2013) 1.05
Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. J Neuroinflammation (2012) 1.02
Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol (2007) 1.02
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One (2013) 1.00
Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci (2002) 1.00
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol Cell Neurosci (2007) 0.98
Integrin-binding RGD peptides induce rapid intracellular calcium increases and MAPK signaling in cortical neurons. Mol Cell Neurosci (2006) 0.98
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol (2011) 0.97
Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neurones. Mol Cell Neurosci (2008) 0.96
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett (2013) 0.95
Leptin induces interleukin-1beta release from rat microglial cells through a caspase 1 independent mechanism. J Neurochem (2007) 0.95
Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci (2006) 0.95
Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem (2005) 0.94
Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab (2003) 0.94
Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection. J Neuroinflammation (2012) 0.93
Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br J Pharmacol (2002) 0.92
The dynamics and mechanisms of interleukin-1alpha and beta nuclear import. Traffic (2008) 0.92
No role for interleukin-18 in acute murine stroke-induced brain injury. J Cereb Blood Flow Metab (2003) 0.92
Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage. J Neurointerv Surg (2012) 0.91
Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways. Curr Neurovasc Res (2010) 0.91
PRL-releasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology (2002) 0.91
The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain? Mol Neurobiol (2003) 0.90
Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci (2005) 0.89
IL-1 beta signalling in glial cells in wildtype and IL-1RI deficient mice. Br J Pharmacol (2002) 0.89
Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα. Ann Neurol (2014) 0.89
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg Med Chem Lett (2011) 0.88
Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine (2012) 0.88
The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation (2014) 0.88
Interleukin-18 induces expression and release of cytokines from murine glial cells: interactions with interleukin-1 beta. J Neurochem (2003) 0.87
Mechanisms of interleukin-6 synthesis and release induced by interleukin-1 and cell depolarisation in neurones. Mol Cell Neurosci (2007) 0.87
Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. Dis Model Mech (2013) 0.86
Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study. Int J Stroke (2011) 0.86
A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology (2007) 0.86
Identification of a truncated IL-18R beta mRNA: a putative regulator of IL-18 expressed in rat brain. J Neuroimmunol (2003) 0.85
Correlation of systemic inflammatory response with infarct volume in acute ischemic stroke patients. Stroke (2004) 0.85
Interleukin-1 mediates neuroinflammatory changes associated with diet-induced atherosclerosis. J Am Heart Assoc (2012) 0.85
The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses. Cytokine (2005) 0.84
Pannexin-1-dependent caspase-1 activation and secretion of IL-1beta is regulated by zinc. Eur J Immunol (2009) 0.83
IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol (2003) 0.82
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett (2008) 0.82
Site-specific actions of interleukin-1 on excitotoxic cell death in the rat striatum. Brain Res (2002) 0.81
Gene regulation by IL-1beta independent of IL-1R1 in the mouse brain. Glia (2006) 0.81
Interleukin-1 exacerbates focal cerebral ischemia and reduces ischemic brain temperature in the rat. Magn Reson Med (2008) 0.81
Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. Expert Opin Drug Metab Toxicol (2011) 0.79
An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro blood-brain barrier model. Brain Res (2012) 0.79
Neuronal injury induces the release of pro-interleukin-1beta from activated microglia in vitro. Brain Res (2008) 0.78
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorg Med Chem Lett (2008) 0.77
Differential actions of IL-1 alpha and IL-1 beta in glial cells share common IL-1 signalling pathways. Neuroreport (2005) 0.77
Requirement for interleukin-1 to drive brain inflammation reveals tissue-specific mechanisms of innate immunity. Eur J Immunol (2014) 0.76
Time for a putsch of the l'oreal consultants? BMJ (2013) 0.75
Up-regulation of IL-18BP, but not IL-18 mRNA in rat liver by LPS. Cytokine (2003) 0.75